Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Cross Country Healthcare (CCRN) over the last 16 years, with Q3 2025 value amounting to $4.1 million.

  • Cross Country Healthcare's Depreciation & Amortization (CF) fell 911.52% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year decrease of 560.83%. This contributed to the annual value of $18.2 million for FY2024, which is 80.12% down from last year.
  • Cross Country Healthcare's Depreciation & Amortization (CF) amounted to $4.1 million in Q3 2025, which was down 911.52% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Cross Country Healthcare's Depreciation & Amortization (CF) ranged from a high of $4.9 million in Q1 2023 and a low of $2.2 million during Q2 2021
  • Its 5-year average for Depreciation & Amortization (CF) is $3.8 million, with a median of $4.1 million in 2025.
  • In the last 5 years, Cross Country Healthcare's Depreciation & Amortization (CF) crashed by 4403.16% in 2021 and then soared by 8036.04% in 2023.
  • Over the past 5 years, Cross Country Healthcare's Depreciation & Amortization (CF) (Quarter) stood at $2.7 million in 2021, then grew by 16.25% to $3.2 million in 2022, then surged by 41.4% to $4.5 million in 2023, then dropped by 2.91% to $4.3 million in 2024, then dropped by 5.83% to $4.1 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $4.1 million for Q3 2025, versus $4.1 million for Q2 2025 and $4.8 million for Q1 2025.